PFS
RVNC

Prospera Financial Services’s Revance Therapeutics, Inc. RVNC Stock Holding History

Prospera Financial Services’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,272
Closed -$122K – 2680
2022
Q1 		$122K Buy
+6,272
New +$95.1K 0.01% 1049

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Prospera Financial Services's RVNC Position: Q2 2022 in Review

Prospera Financial Services sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2022, closing a stake of 6,272 shares — an estimated $122K sold.

Prospera Financial Services first reported a position in RVNC in Q1 2022 and held it in 1 quarter. The position peaked at $122K in Q1 2022. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2022.

  • Prospera Financial Services reported no remaining Revance Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 6,272 Revance Therapeutics, Inc. shares in Q2 2022, an estimated $122K.
  • Prospera Financial Services first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's Revance Therapeutics, Inc. position peaked at $122K in Q1 2022.
  • 161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.